These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

741 related items for PubMed ID: 29159802

  • 1. Adenovirus vector-based prime-boost vaccination via heterologous routes induces cervicovaginal CD8+ T cell responses against HPV16 oncoproteins.
    Çuburu N, Khan S, Thompson CD, Kim R, Vellinga J, Zahn R, Lowy DR, Scheper G, Schiller JT.
    Int J Cancer; 2018 Apr 01; 142(7):1467-1479. PubMed ID: 29159802
    [Abstract] [Full Text] [Related]

  • 2. Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody.
    Peng S, Ferrall L, Gaillard S, Wang C, Chi WY, Huang CH, Roden RBS, Wu TC, Chang YN, Hung CF.
    mBio; 2021 Jan 19; 12(1):. PubMed ID: 33468698
    [Abstract] [Full Text] [Related]

  • 3. Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8+ T-cell-Mediated Tumor Control in the Genital Tract.
    Sun YY, Peng S, Han L, Qiu J, Song L, Tsai Y, Yang B, Roden RB, Trimble CL, Hung CF, Wu TC.
    Clin Cancer Res; 2016 Feb 01; 22(3):657-69. PubMed ID: 26420854
    [Abstract] [Full Text] [Related]

  • 4. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
    Welters MJ, Kenter GG, Piersma SJ, Vloon AP, Löwik MJ, Berends-van der Meer DM, Drijfhout JW, Valentijn AR, Wafelman AR, Oostendorp J, Fleuren GJ, Offringa R, Melief CJ, van der Burg SH.
    Clin Cancer Res; 2008 Jan 01; 14(1):178-87. PubMed ID: 18172269
    [Abstract] [Full Text] [Related]

  • 5. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.
    Seo SH, Jin HT, Park SH, Youn JI, Sung YC.
    Vaccine; 2009 Sep 25; 27(42):5906-12. PubMed ID: 19651174
    [Abstract] [Full Text] [Related]

  • 6. Vaccination of full-length HPV16 E6 or E7 protein inhibits the growth of HPV16 associated tumors.
    Li YL, Qiu XH, Shen C, Liu JN, Zhang J.
    Oncol Rep; 2010 Nov 25; 24(5):1323-9. PubMed ID: 20878127
    [Abstract] [Full Text] [Related]

  • 7. Immunological protection against HPV16 E7-expressing human esophageal cancer cell challenge by a novel HPV16-E6/E7 fusion protein based-vaccine in a Hu-PBL-SCID mouse model.
    Lu Y, Zhang Z, Liu Q, Liu B, Song X, Wang M, Zhao X, Zhao Q.
    Biol Pharm Bull; 2007 Jan 25; 30(1):150-6. PubMed ID: 17202676
    [Abstract] [Full Text] [Related]

  • 8. Intravaginal immunization with HPV vectors induces tissue-resident CD8+ T cell responses.
    Çuburu N, Graham BS, Buck CB, Kines RC, Pang YY, Day PM, Lowy DR, Schiller JT.
    J Clin Invest; 2012 Dec 25; 122(12):4606-20. PubMed ID: 23143305
    [Abstract] [Full Text] [Related]

  • 9. Toll-like receptor agonist imiquimod facilitates antigen-specific CD8+ T-cell accumulation in the genital tract leading to tumor control through IFNγ.
    Soong RS, Song L, Trieu J, Knoff J, He L, Tsai YC, Huh W, Chang YN, Cheng WF, Roden RB, Wu TC, Trimble CL, Hung CF.
    Clin Cancer Res; 2014 Nov 01; 20(21):5456-67. PubMed ID: 24893628
    [Abstract] [Full Text] [Related]

  • 10. A novel therapeutic vaccine composed of a rearranged human papillomavirus type 16 E6/E7 fusion protein and Fms-like tyrosine kinase-3 ligand induces CD8+ T cell responses and antitumor effect.
    Li J, Chen S, Ge J, Lu F, Ren S, Zhao Z, Pu X, Chen X, Sun J, Gu Y.
    Vaccine; 2017 Nov 07; 35(47):6459-6467. PubMed ID: 29029939
    [Abstract] [Full Text] [Related]

  • 11. Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response.
    van Poelgeest MI, Welters MJ, Vermeij R, Stynenbosch LF, Loof NM, Berends-van der Meer DM, Löwik MJ, Hamming IL, van Esch EM, Hellebrekers BW, van Beurden M, Schreuder HW, Kagie MJ, Trimbos JB, Fathers LM, Daemen T, Hollema H, Valentijn AR, Oostendorp J, Oude Elberink JH, Fleuren GJ, Bosse T, Kenter GG, Stijnen T, Nijman HW, Melief CJ, van der Burg SH.
    Clin Cancer Res; 2016 May 15; 22(10):2342-50. PubMed ID: 26813357
    [Abstract] [Full Text] [Related]

  • 12. GTL001 and bivalent CyaA-based therapeutic vaccine strategies against human papillomavirus and other tumor-associated antigens induce effector and memory T-cell responses that inhibit tumor growth.
    Esquerré M, Momot M, Goubier A, Gonindard C, Leung-Theung-Long S, Misseri Y, Bissery MC.
    Vaccine; 2017 Mar 13; 35(11):1509-1516. PubMed ID: 28196735
    [Abstract] [Full Text] [Related]

  • 13. Design and evaluation of a multi-epitope DNA vaccine against HPV16.
    Zhu L, Cui X, Yan Z, Tao Y, Shi L, Zhang X, Yao Y, Shi L.
    Hum Vaccin Immunother; 2024 Dec 31; 20(1):2352908. PubMed ID: 38780076
    [Abstract] [Full Text] [Related]

  • 14. Low-dose adenovirus vaccine encoding chimeric hepatitis B virus surface antigen-human papillomavirus type 16 E7 proteins induces enhanced E7-specific antibody and cytotoxic T-cell responses.
    Báez-Astúa A, Herráez-Hernández E, Garbi N, Pasolli HA, Juárez V, Zur Hausen H, Cid-Arregui A.
    J Virol; 2005 Oct 31; 79(20):12807-17. PubMed ID: 16188983
    [Abstract] [Full Text] [Related]

  • 15. Development of an adenoviral vaccine against E6 and E7 oncoproteins to prevent growth of human papillomavirus-positive cancer.
    Lee DW, Anderson ME, Wu S, Lee JH.
    Arch Otolaryngol Head Neck Surg; 2008 Dec 31; 134(12):1316-23. PubMed ID: 19075129
    [Abstract] [Full Text] [Related]

  • 16. A Genetically Modified attenuated Listeria Vaccine Expressing HPV16 E7 Kill Tumor Cells in Direct and Antigen-Specific Manner.
    Jia YY, Tan WJ, Duan FF, Pan ZM, Chen X, Yin YL, Jiao XA.
    Front Cell Infect Microbiol; 2017 Dec 31; 7():279. PubMed ID: 28706878
    [Abstract] [Full Text] [Related]

  • 17. Prime-boost therapeutic vaccination in mice with DNA/DNA or DNA/Fowlpox virus recombinants expressing the Human Papilloma Virus type 16 E6 and E7 mutated proteins fused to the coat protein of Potato virus X.
    Illiano E, Bissa M, Paolini F, Zanotto C, De Giuli Morghen C, Franconi R, Radaelli A, Venuti A.
    Virus Res; 2016 Oct 02; 225():82-90. PubMed ID: 27664839
    [Abstract] [Full Text] [Related]

  • 18. First-in-Human Phase I Clinical Trial of an SFV-Based RNA Replicon Cancer Vaccine against HPV-Induced Cancers.
    Komdeur FL, Singh A, van de Wall S, Meulenberg JJM, Boerma A, Hoogeboom BN, Paijens ST, Oyarce C, de Bruyn M, Schuuring E, Regts J, Marra R, Werner N, Sluis J, van der Zee AGJ, Wilschut JC, Allersma DP, van Zanten CJ, Kosterink JGW, Jorritsma-Smit A, Yigit R, Nijman HW, Daemen T.
    Mol Ther; 2021 Feb 03; 29(2):611-625. PubMed ID: 33160073
    [Abstract] [Full Text] [Related]

  • 19. Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines.
    Bellone S, El-Sahwi K, Cocco E, Casagrande F, Cargnelutti M, Palmieri M, Bignotti E, Romani C, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD.
    J Virol; 2009 Jul 03; 83(13):6779-89. PubMed ID: 19386711
    [Abstract] [Full Text] [Related]

  • 20. A Prime-Pull-Amplify Vaccination Strategy To Maximize Induction of Circulating and Genital-Resident Intraepithelial CD8+ Memory T Cells.
    Çuburu N, Kim R, Guittard GC, Thompson CD, Day PM, Hamm DE, Pang YS, Graham BS, Lowy DR, Schiller JT.
    J Immunol; 2019 Feb 15; 202(4):1250-1264. PubMed ID: 30635393
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.